ReviewCancers2017
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.
Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,048 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,048 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,908 citations in OpenAlex.
- Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Association of EGFR and EGF gene polymorphisms with cervical cancer in a case-control study and cross-cancer meta-analysis.Scientific reports · 2026Pooled it
- Malignant Transformation of Oral Leukoplakia and Proliferative Verrucous Leukoplakia and Its Biomarker Predictors: A Systematic Umbrella Review.Head & neck · 2026Pooled it
- Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.Bioactive materials · 2027Article
- Perspectives of EGFR co-targeting with nanocarriers for anti-TNBC purposes.Genes & diseases · 2026Review
- Biomimetic Nanocarriers for Glioblastoma Therapy: Translational Advances and Strategic Challenges.Cancers · 2026Review
- Article
- MACC1 Hyperactivates Receptor Tyrosine Kinase Signaling Through Phosphorylation-Dependent Adaptor Activity in Colorectal Cancer Cells.Biomolecules · 2026Article
- Role of cell wall-associated kinases in plant development and defense responses.Molecular biology reports · 2026Review
- Genome-Wide Mining of lncRNAs Reveals Their Potential Regulatory Role in the Evolution of Viviparity.Integrative zoology · 2026Article
- Postnatal Cell-Type-Specific Localization of EGFR and Its Ligands (EGF, TGF-α and AREG) in the Rat Testis.Anatomia, histologia, embryologia · 2026Article
- Repurposing antifungal drugs for Oral squamous cell carcinoma using network pharmacology, molecular docking and molecular dynamics approaches.Journal, genetic engineering & biotechnology · 2026Article
- Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2026Article
- NExON-Bayes: a Bayesian approach to network estimation informed by ordinal covariates.Bioinformatics (Oxford, England) · 2026Article
- Novel protein biomarkers for risk stratification and personalized medicine.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Marbofloxacin Suppresses Breast Cancer Growth Through Oxidative Stress and Metabolic Reprogramming with Predicted HSP90AA1-EGFR Network Modulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Deciphering the Molecular Landscape of Squamous Cell Carcinoma of the Anal Canal: From Biology to Precision Oncology.Cancers · 2026Review
- Designing lysate-based hydrogels for on-demand therapy.Journal of pharmaceutical analysis · 2026Review
- Ascl1 promotes OPC specification across species and central nervous system regions and its gliogenic function is regulated by phosphorylation.Developmental biology · 2026Article
988 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer. Various mechanisms mediate the upregulation of EGFR activity, including common mutations and truncations to its extracellular domain, such as in the EGFRvIII truncations, as well as to its kinase domain, such as the L858R and T790M mutations, or the exon 19 truncation. These EGFR aberrations over-activate downstream pro-oncogenic signaling pathways, including the RAS-RAF-MEK-ERK MAPK and AKT-PI3K-mTOR pathways. These pathways then activate many biological outputs that are beneficial to cancer cell proliferation, including their chronic initiation and progression through the cell cycle. Here, we review the molecular mechanisms that regulate EGFR signal transduction, including the EGFR structure and its mutations, ligand binding and EGFR dimerization, as well as the signaling pathways that lead to G1 cell cycle progression. We focus on the induction of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.